Gut microbial metabolites in inflammatory bowel disease: immunological mechanisms regulating Treg/Th17 balance and therapeutic potential - PubMed
7 hours ago
- #IBD
- #Treg/Th17 balance
- #gut microbiota
- Inflammatory bowel disease (IBD) is a chronic inflammatory disorder influenced by genetic, environmental, and immune factors.
- Gut microbiota and its metabolites, like SCFAs, tryptophan derivatives, and bile acids, play a key role in intestinal immune homeostasis.
- Dysbiosis and altered metabolite levels disrupt the Treg/Th17 balance, driving IBD pathogenesis.
- Microbial metabolites regulate Treg/Th17 differentiation via metabolic reprogramming, epigenetic changes, and immune microenvironment modulation.
- Therapeutic strategies targeting the microbiota-metabolism-immune axis include dietary interventions, probiotics, fecal microbiota transplantation, and small-molecule modulators.
- Future research directions involve multi-omics, spatial biology, and organoid models for personalized IBD treatments.